Scancell announces that the Annual General Meeting ("AGM") relating to the Company's financial year ended 30 April 2013, will be held at 11.00 a.m. on 1 November 2013 at the offices of FTI Consulting, Holborn Gate, 26 Southampton Buildings, London, WC2A 1PB.
The Notice convening the AGM is being sent to shareholders today and will be available on the company's website www.scancell.co.uk
| Dr Richard Goodfellow, Joint CEO |
Scancell Holdings Plc |
+ 44 (0) 74 2323 0 497 |
| Professor Lindy Durrant, Joint CEO |
Scancell Holdings Plc |
|
| Camilla Hume/Stephen Keys |
Cenkos Securities plc |
+ 44 (0) 20 7397 8900 |
| Mo Noonan/Simon Conway |
FTI Consulting |
+ 44 (0) 20 7831 3113 |
| Kim von Ahn |
Dr. Reuter Investor Relations |
[+49 251 980 1561] |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.